Effects of bronchodilation on biomarkers of peripheral airway inflammation in COPD

Pharmacological Research

Volumn 133, Issue , 2018, Pages 160-169

  Santus, Pierachille ^a   Radovanovic, Dejan ^a   Mascetti, Susanna ^b   Pauletti, Alessia ^b   Valenti, Vincenzo ^c   Mantero, Marco ^c   Papi, Alberto ^b   Contoli, Marco ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

Biomarker; Bronchodilator; COPD; Mechanical stress; Nitric oxide; Small airways

Indexed keywords

FORMOTEROL FUMARATE; SALMETEROL XINAFOATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BIOLOGICAL MARKER; BRONCHODILATING AGENT; NITRIC OXIDE;

ADULT; AGED; ARTICLE; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DYSPNEA; EXHALED ALVEOLAR FRACTION OF NITRIC OXIDE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG DIFFUSION; LUNG MECHANICS; LUNG TRANSFER FACTOR; LUNG VENTILATION; MALE; MULTICENTER STUDY; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESIDUAL VOLUME; RESPIRATORY TRACT INFLAMMATION; SEX RATIO; TOTAL LUNG CAPACITY; VITAL CAPACITY; CLINICAL TRIAL; METABOLISM; PATHOPHYSIOLOGY; PHASE 4 CLINICAL TRIAL;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; AGED; BIOMARKERS; BRONCHODILATOR AGENTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORMOTEROL FUMARATE; HUMANS; MALE; NITRIC OXIDE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SALMETEROL XINAFOATE;

EID: 85047399200     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2018.05.010     Document Type: Article

References (50)

1. Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease Updated 2018. 2018 Date last updated: November 2017. Date last accessed: January 12 2018. http://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf.
2. Santus, P., Radovanovic, D., Henchi, S., Di Marco, F., Centanni, S., D'Angelo, E., Pecchiari, M., Assessment of acute bronchodilator effects from specific airway resistance changes in stable COPD patients. Respir. Physiol. Neurobiol. 197 (2014), 36–45, 10.1016/j.resp.2014.03.012.
3. Santus, P., Radovanovic, D., Paggiaro, P., Papi, A., Sanduzzi, A., Scichilone, N., Braido, F., Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol. Eur. J. Intern. Med. 26:6 (2015), 379–384, 10.1016/j.ejim.2015.05.001.
4. Pecchiari, M., Radovanovic, D., Santus, P., D'Angelo, E., Airway occlusion assessed by single breath N2 test and lung P-V curve in healthy subjects and COPD patients. Respir. Physiol. Neurobiol. 234 (2016), 60–68, 10.1016/j.resp.2016.09.006.
5. Pecchiari, M., Santus, P., Radovanovic, D., DʼAngelo, E., Acute effects of long-acting bronchodilators on small airways detected in COPD patients by single-breath N2 test and lung P-V curve. J. Appl. Physiol. 123:5 (2017), 1266–1275, 10.1152/japplphysiol.00493.2017.
6. D'Angelo, E., Pecchiari, M., Baraggia, P., Saetta, M., Balestro, E., Milic-Emili, J., Low-volume ventilation causes peripheral airway injury and increased airway resistance in normal rabbits. J. Appl. Physiol. 92 (2002), 949–956, 10.1152/japplphysiol.00776.2001.
7. D'Angelo, E., Pecchiari, M., Saetta, M., Balestro, E., Milic-Emili, J., Dependence of lung injury on inflation rate during low-volume ventilation in normal open-chest rabbits. J. Appl. Physiol. 97 (2004), 260–268.
8. Pijnenburg, M.W.H., Exhaled nitric oxide in respiratory diseases other than asthma. Horvath, I., de Jongste, J.C., (eds.) Exhaled Biomarkers. European Respiratory Monograph, 2010, European Respiratory Society, Plymouth, UK, 45–55.
9. Ricciardolo, F.L., Caramori, G., Ito, K., Capelli, A., Brun, P., Abatangelo, G., Papi, A., Chung, K.F., Adcock, I., Barnes, P.J., Donner, C.F., Rossi, A., Di Stefano, A., Nitrosative stress” in the bronchial mucosa of severe chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 116 (2005), 1028–1035, 10.1016/j.jaci.2005.06.034.
10. Brindicci, C., Ito, K., Resta, O., Pride, N.B., Barnes, P.J., Kharitonov, S.A., Exhaled nitric oxide from lung periphery is increased in COPD. Eur. Respir. J. 26:1 (2005), 52–59, 10.1183/09031936.04.00125304.
11. Faisy, C., Pinto, F.M., Le Guen, M., Naline, E., Grassin Delyle, S., Sage, E., Candenas, M.L., Devillier, P., Airway response to acute mechanical stress in a human bronchial model of stretch. Crit. Care, 15(5), 2011, R208, 10.1186/cc10443.
12. Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R.O., Burgos, F., Casaburi, R., Coates, A., van der Grinten, C.P., Gustafsson, P., Hankinson, J., Jensen, R., Johnson, D.C., MacIntyre, N., McKay, R., Miller, M.R., Navajas, D., Pedersen, O.F., Wanger, J., Interpretative strategies for lung function tests. Eur. Respir. J. 26:5 (2005), 948–968, 10.1183/09031936.05.00035205.
13. Daley-Yates, P.T., Inhaled corticosteroids: potency, dose equivalence and therapeutic index. Br. J. Clin. Pharmacol. 80:3 (2015), 372–380, 10.1111/bcp.12637.
14. Lavorini, F., Pedersen, S., Usmani, O.S., Aerosol drug management improvement team (ADMIT). Dilemmas, confusion, misconceptions related small airways directed therapy. Chest 151:6 (2017), 1345–1355, 10.1016/j.chest.2016.07.035.
15. Wanger, J., Clausen, J.L., Coates, A., Pedersen, O.F., Brusasco, V., Burgos, F., Casaburi, R., Crapo, R., Enright, P., van der Grinten, C.P., Gustafsson, P., Hankinson, J., Jensen, R., Johnson, D., Macintyre, N., McKay, R., Miller, M.R., Navajas, D., Pellegrino, R., Viegi, G., Standardisation of the measurement of lung volumes. Eur. Respir. J. 26 (2005), 511–522, 10.1183/09031936.05.00035005.
16. Macintyre, N., Crapo, R.O., Viegi, G., Johnson, D.C., van der Grinten, C.P., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Enright, P., Gustafsson, P., Hankinson, J., Jensen, R., McKay, R., Miller, M.R., Navajas, D., Pedersen, O.F., Pellegrino, R., Wanger, J., Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur. Respir. J. 26 (2005), 720–735, 10.1183/09031936.05.00034905.
17. Hughes, J.M., Pride, N.B., Examination of the carbon monoxide diffusing capacity (DLCO) in relation to its KCO and VA components. Am. J. Respir. Crit. Care Med. 186:2 (2012), 132–139, 10.1164/rccm.201112-2160CI.
18. Santus, P., Radovanovic, D., Balzano, G., Pecchiari, M., Raccanelli, R., Sarno, N., Di Marco, F., Jones, P.W., Carone, M., Improvements in lung diffusion capacity following pulmonary rehabilitation in COPD with and without ventilation inhomogeneity. Respiration 92 (2016), 295–307, 10.1159/000448847.
19. American Thoracic Society, Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am. J. Respir. Crit. Care Med. 159 (1999), 321–340, 10.1164/ajrccm.159.1.ats898.
20. MahleCr, D.A., Wells, C.K., Evaluation of clinical methods for rating dyspnea. Chest 93 (1988), 580–586, 10.1378/chest.93.3.580.
21. American Thoracic Society, European Respiratory Society, ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide. Am. J. Respir. Crit. Care Med. 171:8 (2005), 912–930, 10.1164/rccm.200406-710ST.
22. Tsoukias, N.M., George, S.C., A two-compartment model of pulmonary nitric oxide exchange dynamics. J. Appl. Physiol. 85:2 (1998), 653–666, 10.1152/jappl.1998.85.2.653.
23. Paredi, P., Kharitonov, S.A., Meah, S., Barnes, P.J., Usmani, O.S., A novel approach to partition central and peripheral airway nitric oxide. Chest 145:1 (2014), 113–119, 10.1378/chest.13-0843.
24. George, S.C., Hogman, M., Permutt, S., Silkoff, P.E., Modeling pulmonary nitric oxide exchange. J. Appl. Physiol. 96:3 (2004), 831–839, 10.1152/japplphysiol.00950.2003.
25. Silkoff, P.E., Wakita, S., Chatkin, J., Ansarin, K., Gutierrez, C., Caramori, M., McClean, P., Slutsky, A.S., Zamel, N., Chapman, K.R., Exhaled nitric oxide after beta2-agonist inhalation and spirometry in asthma. Am. J. Respir. Crit. Care Med. 159:3 (1999), 940–944, 10.1164/ajrccm.159.3.9805044.
26. Quanjer, P.H., Standardized lung function testing. Bull. Eur. Physiopathol. Respir. 19:Suppl. (5) (1983), 22–61.
27. Yates, D.H., Kharitonov, S.A., Barnes, P.J., Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients. Eur. Respir. J. 10:7 (1997), 1483–1488.
28. Horváth, I., Barnes, P.J., Loukides, S., et al. A European respiratory society technical standard: exhaled biomarkers in lung disease. Eur. Respir. J., 49(4), 2017, 1600965.
29. Lehouck, A., Carremans, C., De Bent, K., Decramer, M., Janssens, W., Alveolar and bronchial exhaled nitric oxide in chronic obstructive pulmonary disease. Respir. Med. 104:7 (2010), 1020–1026, 10.1016/j.rmed.2010.01.001.
30. Corradi, M., Majori, M., Cacciani, G.C., Consigli, G.F., de'Munari, E., Pesci, A., Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax 54:7 (1999), 572–575.
31. Högman, M., Holmkvist, T., Wegener, T., et al. Extended NO analysis applied to patients with COPD, allergic asthma and allergic rhinitis. Respir. Med. 96:1 (2002), 24–30.
32. Condorelli, P., Shin, H., Aledia, A., Silkoff, P., George, S., A simple technique to characterize proximal and peripheral nitric oxide exchange using constant flow exhalations and an axial diffusion model. J. Appl. Physiol. 102:1 (2007), 417–425, 10.1152/japplphysiol.00533.2006.
33. Karvonen, T., Kankaanranta, H., Saarelainen, S., Moilanen, E., Lehtimäki, L., Comparison of feasibility and estimates of central and peripheral nitric oxide parameters by different mathematical models. J. Breath Res., 11(4), 2017, 047102, 10.1088/1752-7163/aa7cc0.
34. Gelb, A.F., George, S.C., Camacho, F., Fraser, C., Flynn Taylor, C., Shakkottai, S., Increased nitric oxide concentrations in the small airway of older normal subjects. Chest 139:2 (2011), 368–375, 10.1378/chest.10-1157.
35. Milic-Emili, J., Pecchiari, M., D'Angelo, E., Pathophysiology of chronic obstructive pulmonary disease. Curr. Respir. Med. Rev. 4 (2008), 249–256, 10.2174/ 157339808786263842.
36. Zhao, H., Li, R., Lv, Y., Dong, H., Yao, L., Wu, Y., Xiao, G., Cai, S., Albuterol inhalation increases FeNO level in steroid-naive asthmatics but not COPD patients with reversibility. Clin. Respir. J. 11:3 (2017), 328–336, 10.1111/crj.12340.
37. Amer, M., Cowan, J., Gray, A., Brockway, B., Dummer, J., Effect of inhaled β2-agonist on exhaled nitric oxide in chronic obstructive pulmonary disease. PLoS One, 11(6), 2016, e0157019, 10.1371/journal.pone.0157019.
38. Antus, B., Barta, I., Horvath, I., Csiszer, E., Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 15:3 (2010), 472–477, 10.1111/j.1440-1843.2010.01711.x.
39. Mitsufuji, H., Kobayashi, H., Imasaki, T., Ichikawa, T., Kawakami, T., Tomita, T., Acute changes in bronchoconstriction influences exhaled nitric oxide level. Jpn. J. Physiol. 51:2 (2001), 151–157, 10.2170/jjphysiol.51.151.
40. Michils, A., Malinovschi, A., Haccuria, A., Michiels, S., Van Muylem, A., Different patterns of exhaled nitric oxide response to β2-agonists in asthmatic patients according to the site of bronchodilation. J. Allergy Clin. Immunol. 137:3 (2016), 806–812, 10.1016/j.jaci.2015.09.054.
41. Bhatt, S.P., Soler, X., Wang, X., Murray, S., Anzueto, A.R., Beaty, T.H., Boriek, A.M., Casaburi, R., Criner, G.J., Diaz, A.A., Dransfield, M.T., Curran-Everett, D., Galbán, C.J., Hoffman, E.A., Hogg, J.C., Kazerooni, E.A., Kim, V., Kinney, G.L., Lagstein, A., Lynch, D.A., Make, B.J., Martinez, F.J., Ramsdell, J.W., Reddy, R., Ross, B.D., Rossiter, H.B., Steiner, R.M., Strand, M.J., van Beek, E.J., Wan, E.S., Washko, G.R., Wells, J.M., Wendt, C.H., Wise, R.A., Silverman, E.K., Crapo, J.D., Bowler, R.P., Han, M.K., COPDGene investigators, Association between functional small airway disease and FEV1 decline in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 194:2 (2016), 178–184, 10.1164/rccm.201511-2219OC.
42. Wiggs, B.R., Bosken, C., Pare, P.D., James, A., Hogg, J.C., A model of airway narrowing in asthma and in chronic obstructive pulmonary disease. Am. Rev. Respir. Dis. 145 (1992), 1251–1258, 10.1164/ajrccm/145.6.1251.
43. Eliseeva, E.V., Romanova, N.A., Maistrovskaya, Y.V., Regulation of NO-producing function of the lungs with salmeterol. Bull. Exp. Biol. Med. 132:1 (2001), 709–712, 10.1023/A:1012500900601.
44. Eliseeva, E.V., Kulakova, N.V., Nevzorova, V.A., Nitric oxide synthase in bronchial epithelium and nitric oxide metabolites in the lungs of rats with bronchial asthma after fenoterol inhalation. Bull. Exp. Biol. Med. 130:8 (2000), 763–765.
45. Ten Berge, R.E., Weening, E.C., Roffel, A.F., Zaagsma, J., Beta 2- but not beta 3-adrenoceptors mediate prejunctional inhibition of non-adrenergic non-cholinergic contraction of guinea pig main bronchi. Eur J. Pharmacol. 275:2 (1995), 199–206, 10.1016/0014-2999(94)00771-X.
46. Santus, P., Radovanovic, D., Di Marco, F., Raccanelli, R., Valenti, V., Centanni, S., Faster reduction in hyperinflation and improvement in lung ventilation inhomogeneity promoted by aclidinium compared to glycopyrronium in severe stable COPD patients. A randomized crossover study. Pulm. Pharmacol. Ther. 35 (2015), 42–49, 10.1016/j.pupt.2015.11.001.
47. Santus, P., Buccellati, C., Centanni, S., Fumagalli, F., Busatto, P., Blasi, F., Sala, A., Bronchodilators modulate inflammation in chronic obstructive pulmonary disease subjects. Pharmacol. Res. 66:4 (2012), 343–348, 10.1016/j.phrs.2012.05.007.
48. Deykin, A., Halpern, O., Massaro, A.F., Drazen, J.M., Israel, E., Expired nitric oxide after bronchoprovocation and repeated spirometry in patients with asthma. Am. J. Respir. Crit. Care Med. 157:3 Pt 1 (1998), 769–775, 10.1164/ajrccm.157.3.9707114.
49. Deykin, A., Massaro, A.F., Coulston, E., Drazen, J.M., Israel, E., Exhaled nitric oxide following repeated spirometry or repeated plethysmography in healthy individuals. Am. J. Respir. Crit. Care Med. 161:4 Pt 1 (2000), 1237–1240, 10.1164/ajrccm.161.4.9904086.
50. Undem, B.J., Kollarik, M., The role of vagal afferent nerves in chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2:4 (2005), 355–360, 10.1513/pats.200504-033SR.